Results 71 to 80 of about 718,948 (303)

Insulin Therapy in Type 2 Diabetes Mellitus: the Need for Early Initiation and Opportunity to Choose

open access: yesMìžnarodnij Endokrinologìčnij Žurnal, 2015
Achieving target values of glycemic profile — the main objective of therapy for type 2 diabetes mellitus (DM2). Early administration of insulin enables not only to lower glycemic parameters quickly and effectively and to compensate carbohydrate ...
I.Yu. Golovach, O.V. Diachоk
doaj   +1 more source

Effects of balloon injury on neointimal hyperplasia in steptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. [PDF]

open access: yes, 2001
BACKGROUND: The mechanisms of increased neointimal hyperplasia after coronary interventions in diabetic patients are still unknown. METHODS AND RESULTS: Glucose and insulin effects on in vitro vascular smooth muscle cell (VSMC) proliferation and ...
Carriero M.V.   +13 more
core  

Cell Therapy for Type 1 Diabetes [PDF]

open access: yes, 2014
Acknowledgements The work described in this review was supported by a grant from the MRC. K.R.M. is supported by a fellowship from the Scottish Translational Medicines and Therapeutics Initiative through the Wellcome Trust.Peer reviewedPublisher ...
Docherty, H. M.   +3 more
core   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

open access: yesMolecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos   +6 more
wiley   +1 more source

A new perspective on metformin therapy in type 1 diabetes [PDF]

open access: yes, 2017
Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited.
Boyle, James G.   +2 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

open access: yesMolecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni   +11 more
wiley   +1 more source

Insuman® Basal, Insuman® Comb, Insuman® Rapid in SoloStar® Disposable Pens — the Only Human Insulins in SoloStar® Disposable Pens in Ukraine

open access: yesMìžnarodnij Endokrinologìčnij Žurnal, 2013
The article deals with insulin therapy in patients with diabetes mellitus. Detailed characteristic of some insulin preparations is provided.
O.V. Korpacheva-Zinych   +2 more
doaj   +1 more source

Structural changes in intestinal enteroendocrine cells after ileal interposition in normal rats [PDF]

open access: yes, 2011
INTRODUCTION: No therapeutic approach has significantly impacted the progression of diabetes. As early improvement of glicaemic control is observed after bariatric surgeries, there is currently a search for surgical procedures that can promote euglycemia
Aparecida Hirata   +16 more
core   +2 more sources

Metformin promotes mitochondrial integrity through AMPK‐signaling in Leber's hereditary optic neuropathy

open access: yesFEBS Open Bio, EarlyView.
Metformin mediates mitochondrial quality control in Leber's hereditary optic neuropathy (LHON) fibroblasts carrying mtDNA mutations. At therapeutic levels, metformin activates AMPK signaling to restore mitochondrial dynamics by promoting fusion and restraining fission, while preserving mitochondrial mass, enhancing autophagy/mitophagy and biogenesis ...
Chatnapa Panusatid   +3 more
wiley   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

open access: yesFEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy